- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03147248
A Phase I/III Study to Evaluate Efficacy, PK and Safety Between CT-P13 SC and CT-P13 IV in Patients With Active RA
A Randomized, Parallel-Group, Phase I/III Study to Evaluate Efficacy, Pharmacokinetics and Safety Between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients With Active Rheumatoid Arthritis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of
- Hanyang University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient is male or female between 18 and 75 years old, inclusive.
- Patient has a diagnosis of RA according to the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for at least 6 months
- Patient has active disease as defined by the presence of 6 or more swollen joints (of 28 assessed), 6 or more tender joints (of 28 assessed) and serum C-reactive protein (CRP) concentration >0.6 mg/dL
- Patient who completed at least 3 months of treatment of oral or parenteral dosing with Methotrexate between 12.5 to 25 mg/kg (between 10 to 25 mg/week in Korea) and on stable dosing with Methotrexate for at least 4 weeks prior to the first administration of the study drug.
Exclusion Criteria:
- Patient who has previously received a biological agent for the treatment of RA and/or a TNFα inhibitor for the treatment of other disease
- Patient who has allergies to any of the excipients of infliximab or any other murine and/or human proteins or patient with a hypersensitivity to immunoglobulin product
- Patient who had current or past history of chronic infection with hepatitis C or human immunodeficiency virus (HIV)-1 or -2 or current infection with hepatitis B
- Patient who had acute infection requiring oral antibiotics within 2 weeks or parenteral injection of antibiotics within 4 weeks prior to the first administration of the study drug, other serious infection within 6 months prior to the first administration of study drug or recurrent herpes zoster or other chronic or recurrent infection within 6 weeks prior to the first administration of the study drug.
- Patient who had an indeterminate result for interferon-γ release assay (IGRA) or latent tuberculosis (TB) at Screening. For Part 2, if IGRA result was indeterminate at Screening, 1 retest was possible during the screening. If the repeated IGRA result was negative, the patient could be included in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Cohort 1: CT-P13 IV 3 mg/kg
CT-P13 Intravenous (IV) (Infliximab), 3 mg/kg by IV infusion every 8 weeks (Part 1)
|
CT-P13 (3 mg/kg) by IV infusion administered as a 2 hour IV infusion per dose every 8 weeks
Other Names:
CT-P13 (90 mg) by single SC injection every other week
Other Names:
CT-P13 (120 mg) by single SC injection every other week
Other Names:
CT-P13 (180 mg) by double SC 90 mg injections every other week
Other Names:
CT-P13 (120 mg) by single SC injection every other week with placebo IV at Weeks 6, 14 and 22.
Other Names:
CT-P13 (3 mg/kg) by IV infusion administered as a 2 hour IV infusion per dose every 8 weeks with placebo SC at Week 6 and every other week thereafter up to Week 28
Other Names:
|
EXPERIMENTAL: Cohort 2: CT-P13 SC 90 mg
CT-P13 Subcutaneous (SC) (Infliximab), 90 mg by SC injection every other week (Part 1)
|
CT-P13 (3 mg/kg) by IV infusion administered as a 2 hour IV infusion per dose every 8 weeks
Other Names:
CT-P13 (90 mg) by single SC injection every other week
Other Names:
CT-P13 (120 mg) by single SC injection every other week
Other Names:
CT-P13 (180 mg) by double SC 90 mg injections every other week
Other Names:
CT-P13 (120 mg) by single SC injection every other week with placebo IV at Weeks 6, 14 and 22.
Other Names:
CT-P13 (3 mg/kg) by IV infusion administered as a 2 hour IV infusion per dose every 8 weeks with placebo SC at Week 6 and every other week thereafter up to Week 28
Other Names:
|
EXPERIMENTAL: Cohort 3: CT-P13 SC 120 mg
CT-P13 SC (Infliximab), 120 mg by SC injection every other week (Part 1)
|
CT-P13 (3 mg/kg) by IV infusion administered as a 2 hour IV infusion per dose every 8 weeks
Other Names:
CT-P13 (90 mg) by single SC injection every other week
Other Names:
CT-P13 (120 mg) by single SC injection every other week
Other Names:
CT-P13 (180 mg) by double SC 90 mg injections every other week
Other Names:
CT-P13 (120 mg) by single SC injection every other week with placebo IV at Weeks 6, 14 and 22.
Other Names:
CT-P13 (3 mg/kg) by IV infusion administered as a 2 hour IV infusion per dose every 8 weeks with placebo SC at Week 6 and every other week thereafter up to Week 28
Other Names:
|
EXPERIMENTAL: Cohort 4: CT-P13 SC 180 mg
CT-P13 SC (Infliximab), 180 mg by SC injection every other week (Part 1)
|
CT-P13 (3 mg/kg) by IV infusion administered as a 2 hour IV infusion per dose every 8 weeks
Other Names:
CT-P13 (90 mg) by single SC injection every other week
Other Names:
CT-P13 (120 mg) by single SC injection every other week
Other Names:
CT-P13 (180 mg) by double SC 90 mg injections every other week
Other Names:
CT-P13 (120 mg) by single SC injection every other week with placebo IV at Weeks 6, 14 and 22.
Other Names:
CT-P13 (3 mg/kg) by IV infusion administered as a 2 hour IV infusion per dose every 8 weeks with placebo SC at Week 6 and every other week thereafter up to Week 28
Other Names:
|
EXPERIMENTAL: Arm 1: CT-P13 SC 120 mg
CT-P13 SC (Infliximab), 120 mg by SC injection every other week with placebo intravenous infusion at Weeks 6, 14 and 22 (Part 2)
|
CT-P13 (3 mg/kg) by IV infusion administered as a 2 hour IV infusion per dose every 8 weeks
Other Names:
CT-P13 (90 mg) by single SC injection every other week
Other Names:
CT-P13 (120 mg) by single SC injection every other week
Other Names:
CT-P13 (180 mg) by double SC 90 mg injections every other week
Other Names:
CT-P13 (120 mg) by single SC injection every other week with placebo IV at Weeks 6, 14 and 22.
Other Names:
CT-P13 (3 mg/kg) by IV infusion administered as a 2 hour IV infusion per dose every 8 weeks with placebo SC at Week 6 and every other week thereafter up to Week 28
Other Names:
|
ACTIVE_COMPARATOR: Arm 2: CT-P13 IV 3 mg/kg
CT-P13 IV (Infliximab), 3 mg/kg by IV infusion every 8 weeks with placebo subcutaneous injection at Week 6 and every 2 weeks thereafter up to Week 28 (Part 2)
|
CT-P13 (3 mg/kg) by IV infusion administered as a 2 hour IV infusion per dose every 8 weeks
Other Names:
CT-P13 (90 mg) by single SC injection every other week
Other Names:
CT-P13 (120 mg) by single SC injection every other week
Other Names:
CT-P13 (180 mg) by double SC 90 mg injections every other week
Other Names:
CT-P13 (120 mg) by single SC injection every other week with placebo IV at Weeks 6, 14 and 22.
Other Names:
CT-P13 (3 mg/kg) by IV infusion administered as a 2 hour IV infusion per dose every 8 weeks with placebo SC at Week 6 and every other week thereafter up to Week 28
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area Under the Concentration-time Curve (AUCτ) of Infliximab at Steady State (Part 1)
Time Frame: Weeks 22 (pre-dose to 216 hours post-dose), 24 (14 days after start of administration [SOA] at Week 22), 26 (pre-dose) and 28 (42 days after SOA at Week 22), and Week 30 (pre-dose)
|
For Part 1, the primary pharmacokinetic (PK) endpoint of the AUCτ (area under the concentration-time curve) at steady state between Week 22 and Week 30 was analyzed in patients who received all doses (full) of study drug up to Week 30 (prior to Week 30) in the PK population.
All patients in SC cohorts were randomly assigned at Week 14 in a 1:1 ratio to either Group A or B for PK monitoring visit period (Week 22 and Week 30).
Therefore, AUCτ was calculated at Week 22 for Cohort 1: CT-P13 IV 3 mg/kg, Weeks 22 and 26 for Group A of SC cohorts, and Weeks 24 and 28 for Group B of SC cohorts.
|
Weeks 22 (pre-dose to 216 hours post-dose), 24 (14 days after start of administration [SOA] at Week 22), 26 (pre-dose) and 28 (42 days after SOA at Week 22), and Week 30 (pre-dose)
|
Change From Baseline of Disease Activity Score Using 28 Joint Counts (DAS28) (CRP) at Week 22 (Part 2)
Time Frame: Week 22
|
For Part 2, the primary efficacy endpoint was to demonstrate that CT-P13 SC 120 mg is non-inferior to CT-P13 IV 3 mg/kg at Week 22, as determined by clinical response according to mean change from baseline in DAS28 (CRP) at Week 22, using Analysis of Covariance (ANCOVA).
Change from baseline for ANCOVA was defined as decrease from baseline and calculated as (DAS28 [CRP] at baseline - DAS28 [CRP] at Week 22).
DAS28 (CRP) was calculated using the following formula: DAS28 (CRP) equals(=) (0.56 multiplied by [*] the square root [√] of TJC28 [tender joint count]) plus (+) (0.28 * √ of SJC28 [swollen joint count]) + (0.36 * the natural logarithm [ln](CRP [mg/L] + 1)) + (0.014 * patient global disease activity [GH] on visual analogue assessment [VAS]) + 0.96.
DAS28 (CRP) provides a number on a scale from 0 to 10 indicating the current activity of patients with RA.
DAS28 (CRP) score above 5.1 indicates high disease activity, whereas DAS28 (CRP) score below 3.2 indicates low disease activity.
|
Week 22
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Actual Value of Disease Activity Score Using 28 Joint Counts (DAS28 [CRP]) (Part 2)
Time Frame: Baseline, Week 2, Week 6, Week 14, Week 22, Week 30, and Week 54
|
The secondary endpoint was defined as descriptive statistics of actual value in disease activity measured by DAS28 (CRP) up to Week 54.
The results up to Week 6 represented the efficacy of CT-P13 IV loading dose (3 mg/kg) regardless of randomized treatment arm (CT-P13 SC or CT-P13 IV) in both treatment arms.
DAS28 (CRP) was calculated according to the following formula: DAS28 (CRP) = (0.56* √ of TJC28) + (0.28 * √ of SJC28) + (0.36 * ln(CRP [mg/L] + 1)) + (0.014 * GH on VAS) + 0.96.
DAS28 (CRP) provides a number on a scale from 0 to 10 indicating the current activity of the patients with RA.
DAS28 (CRP) score above 5.1 indicates high disease activity, whereas DAS28 (CRP) score below 3.2 indicates low disease activity.
|
Baseline, Week 2, Week 6, Week 14, Week 22, Week 30, and Week 54
|
Number of Patients Achieving Clinical Response According to American College of Rheumatology 20% Response (ACR20) (Part 2)
Time Frame: Week 2, Week 6, Week 14, Week 22, Week 30, and Week 54
|
The secondary endpoint was defined as number of patients achieving clinical response according to ACR20 (20% response, defined by ACR) between CT-P13 SC and CT-P13 IV groups. The results up to Week 6 represented the efficacy of CT-P13 IV loading dose (3 mg/kg) regardless of randomized treatment arm (CT-P13 SC or CT-P13 IV). Responder according to the ACR20 criteria defined as, if they are fulfilled, a decrease of at least 20% in number of tender joints and swollen joints (0-28), and 20% improvement in 3 of the followings: patient assessment of pain on VAS (0-100 mm), patient global assessment of disease activity on VAS (0-100 mm) and physician global assessment of disease activity on VAS (0-100 mm), health assessment questionnaire disability index and CRP or ESR (erythrocyte sedimentation rate). |
Week 2, Week 6, Week 14, Week 22, Week 30, and Week 54
|
Observed Trough Serum Concentration (Ctrough) of Infliximab (Part 2)
Time Frame: SC group: Weeks 0, 2, 12, 20, 22, 24, 26, 28, 36, 44, and 52; IV group: Weeks 0, 2, 6, 14, 22, 36, 44, and 52
|
For evaluation of pharmacokinetics (PK), the secondary endpoint was defined as the analysis of trough concentration (concentration before the next study drug administration) of Infliximab up to Week 54.
The samples were collected at Weeks 0, 2 and 6, and every 8 weeks up to Week 54.
During PK monitoring visit (Weeks 22-30), samples were collected every 2 weeks according steady state PK sampling time point.
All patients were randomly assigned at Week 14 in a 1:1:1:1 ratio to one of 4 groups (Groups A, B, C or D) for PK monitoring visit period.
No PK results were obtained at Weeks 6 and 14 for SC group and Weeks 12, 20, 24, 26 and 28 for IV group due to 2 weeks and 8 weeks dosing interval, respectively.
|
SC group: Weeks 0, 2, 12, 20, 22, 24, 26, 28, 36, 44, and 52; IV group: Weeks 0, 2, 6, 14, 22, 36, 44, and 52
|
Mean Actual Value in Serum CRP Concentration (Pharmacodynamic Parameter) (Part 2)
Time Frame: Baseline, Week 2, Week 6, Week 14, Week 22, Week 30, Week 38, Week 46, and Week 54
|
For evaluation of pharmacodynamic (PD), the secondary endpoint was defined as concentration of CRP between 2 treatment groups up to Week 54. The blood samples for CRP were collected at Weeks 0, 2 and 6, and every 8 weeks up to Week 54. Patient who received the other treatment than that to which they were assigned at any point was defined as mis-randomized. One patient in IV group was mis-randomized and analyzed as SC group for PD analysis. |
Baseline, Week 2, Week 6, Week 14, Week 22, Week 30, Week 38, Week 46, and Week 54
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: MoonSun Choi, Celltrion
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CT-P13 3.5 (SC)
- 2016-002125-11 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
Assistance Publique - Hôpitaux de ParisSociete Francaise de RhumatologieRecruiting
-
Amsterdam UMC, location VUmcEuropean CommissionCompletedRheumatoId ArthritisNetherlands, Germany, Portugal, Italy, Hungary, Romania, Slovakia
Clinical Trials on CT-P13
-
IRCCS San RaffaeleRecruitingInflammatory Bowel Diseases | Rheumatologic DiseaseItaly
-
CelltrionCompletedHealth, SubjectiveUnited States
-
CMC Ambroise ParéCelltrion HealthCare France; Paris IBD CenterNot yet recruiting
-
CelltrionPfizerCompletedCrohn's DiseaseUnited States
-
CelltrionCompletedCrohn's Disease | Ulcerative Colitis (Part 2 Only)Korea, Republic of
-
PfizerHospira, now a wholly owned subsidiary of PfizerCompletedRheumatoid Arthritis | Psoriatic Arthritis | Ankylosing Spondylitis | Rheumatoid DiseasesSpain, Canada, Greece, United Kingdom, Germany, Bulgaria, Czechia
-
PfizerHospira, now a wholly owned subsidiary of PfizerCompletedInflammatory Bowel Diseases | Crohn's Disease | Ulcerative ColitisFrance, Spain, United Kingdom, Czechia, Italy, Belgium, Germany, Netherlands, Greece, Finland, Hungary, Portugal, Slovakia
-
Asan Medical CenterNot yet recruitingCrohn Disease | Therapeutic Drug Monitoring | Infliximab | Perianal Fistula Due to Crohn's Disease | Magnetic Resonance Novel Index for Fistula Imaging in Crohn's Disease Score
-
CelltrionCompletedCrohn's DiseaseFrance, Turkey, Czechia, Greece, Latvia, Hungary, Belarus, Israel, United States, Spain, Bulgaria, Serbia, Croatia, Italy, Germany, India, Japan, Mexico, Moldova, Republic of, Peru, Poland, Romania, Russian Federation, Slovakia, South Africa and more
-
CelltrionCompleted